SB
PRME icon

Samsara BioCapital’s Prime Medicine PRME Stock Holding History

Samsara BioCapital’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-405,228
Closed -$806K – 37
2025
Q1 		$806K Hold
405,228
– – 0.14% 27
2024
Q4 		$1.18M Sell
405,228
-135,076
-25% -$474K 0.16% 32
2024
Q3 		$2.09M Hold
540,304
– – 0.4% 28
2024
Q2 		$2.78M Hold
540,304
– – 0.58% 26
2024
Q1 		$3.78M Buy
540,304
+70,000
+15% +$531K 0.59% 27
2023
Q4 		$4.17M Hold
470,304
– – 0.65% 24
2023
Q3 		$4.49M Hold
470,304
– – 1.37% 21
2023
Q2 		$6.89M Hold
470,304
– – 1.21% 17
2023
Q1 		$5.78M Hold
470,304
– – 1.2% 19
2022
Q4 		$8.74M Buy
+470,304
New +$8.5M 1.88% 14

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Samsara BioCapital's PRME Position: Q2 2025 in Review

Samsara BioCapital sold out of Prime Medicine (PRME) in Q2 2025, closing a stake of 405,228 shares — an estimated $806K sold.

Samsara BioCapital first reported a position in PRME in Q4 2022 and held it in 10 quarters. The position peaked at $8.74M in Q4 2022. 121 funds tracked by Wall St. Rank hold PRME as of Q2 2025.

  • Samsara BioCapital reported no remaining Prime Medicine position as of Q2 2025 after selling out during the quarter.
  • Samsara BioCapital sold 405,228 Prime Medicine shares in Q2 2025, an estimated $806K.
  • Samsara BioCapital first reported a position in Prime Medicine in Q4 2022 and held it in 10 quarters.
  • Samsara BioCapital's Prime Medicine position peaked at $8.74M in Q4 2022.
  • 121 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2025.

Based on Samsara BioCapital's 13F filing for Q2 2025, filed 14 Aug 2025.